Blood test can predict progression to Alzheimer's disease
Written By : Isra Zaman
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2023-09-04 03:30 GMT | Update On 2024-01-18 05:57 GMT
Advertisement
Neuroscience researchers at Wayne State University published a review article that confirms the usefulness of neurofilament light (NfL) blood levels to predict the likelihood and rate of progression of neurodegeneration in Alzheimer’s disease. Blood-based NfL is a minimally invasive and easily accessible biomarker, making it a useful clinical biomarker.
Though NfL levels also increase in typical aging as a non-specific marker of neuronal damage, the levels, as well as the rate of increase, seen in Alzheimer’s dementia are higher. Higher serum NfL is also correlated with more severe brain glucose hypometabolism, and diminished white matter integrity, in persons on the Alzheimer’s continuum.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.